Our research group has previously established that the transcription factor v-ets erythroblastosis virus E26 oncogene homolog 1 (Ets-1) is associated with chemotherapeutic resistance in ovarian cancer cells, whereby increased expression of Ets-1 results in decreased sensitivity to cisplatin [8]. This evidence concerns the gene ETS1 and ovarian cancer.